By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

BioGeneriX AG 

Janderstasse 3
High-Tech-Park Mannheim
Mannheim    D-68199  Germany
Phone: 49-621-875561-0 Fax: 49-621-87556-33


SEARCH JOBS


Industry
Biotechnology

Segment
Start Up





Company News
Neose Technologies, Inc. (NTEC) Announces Closing of Asset Sales to Novo Nordisk A/S (NVO) and BioGeneriX AG; First Step in Plan of Liquidation 1/28/2009 6:54:55 AM
Neose Technologies, Inc. (NTEC) to Sell its Assets to Novo Nordisk A/S (NVO) and BioGeneriX AG for $43 Million 9/18/2008 7:07:03 AM
Neose Technologies, Inc. (NTEC) Announces GlycoPEG-GCSF Abstract Accepted for Poster Presentation at IXth World Conference on Clinical Pharmacology and Therapeutics 7/28/2008 10:19:36 AM
BioGeneriX AG and Neose Technologies, Inc. (NTEC) Initiate Phase 2 Trial for GlycoPEG-GCSF 6/23/2008 10:35:53 AM
BioGeneriX AG and Neose Technologies, Inc. (NTEC) Announce Positive Data from Two Phase I Studies of GlycoPEG-GCSF 11/7/2007 10:47:11 AM
BioGeneriX AG and Neose Technologies, Inc. (NTEC) to Host Conference Call to Present GlycoPEG-GCSF Phase I Data 11/1/2007 12:10:12 PM
The Day In Review: BioSimilar Drug Enters Trial 3/21/2007 4:53:46 PM
BioGeneriX AG and Neose Technologies, Inc. (NTEC) Announce Initiation of 2nd Phase I Clinical Trial of GlycoPEG-GCSF; Interim Results From 1st Phase I Trial Show Dose-Dependent Response 3/21/2007 12:37:11 PM
Neose Technologies, Inc. (NTEC) Announces BioGeneriX AG's Initiation Of Phase I Trial Of GlycoPEG-GCSF 11/9/2006 11:29:11 AM
Neose Technologies, Inc. (NTEC) And BioGeneriX AG Announce Second Agreement For A GlycoPEGylated Next-Generation Protein; Milestone Payments Worth Up To $61.5 Million10/19/2005 5:12:35 PM
12
//-->